FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $175,000 | -37.5% | 2,949 | -8.6% | 0.01% | -30.8% |
| Q2 2021 | $280,000 | +17.2% | 3,228 | +11.4% | 0.01% | +8.3% |
| Q1 2021 | $239,000 | +184.5% | 2,898 | +35.9% | 0.01% | +140.0% |
| Q3 2020 | $84,000 | -53.3% | 2,133 | -59.2% | 0.01% | -58.3% |
| Q2 2020 | $180,000 | +78.2% | 5,234 | +14.5% | 0.01% | +50.0% |
| Q1 2020 | $101,000 | +159.0% | 4,572 | +125.3% | 0.01% | +300.0% |
| Q4 2019 | $39,000 | +85.7% | 2,029 | +46.1% | 0.00% | +100.0% |
| Q3 2019 | $21,000 | -89.8% | 1,389 | -86.3% | 0.00% | -92.9% |
| Q2 2019 | $205,000 | +310.0% | 10,108 | +257.7% | 0.01% | +250.0% |
| Q1 2019 | $50,000 | +400.0% | 2,826 | +248.5% | 0.00% | +300.0% |
| Q4 2018 | $10,000 | 0.0% | 811 | +28.1% | 0.00% | 0.0% |
| Q3 2018 | $10,000 | -100.0% | 633 | -75.5% | 0.00% | -66.7% |
| Q2 2018 | $29,325,000 | +244275.0% | 2,586 | +128.0% | 0.00% | +200.0% |
| Q1 2018 | $12,000 | +1100.0% | 1,134 | +422.6% | 0.00% | – |
| Q4 2017 | $1,000 | – | 217 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |